Press releases

31 Aug 2023

UCB presents new data at 35th International Epilepsy Congress (IEC) highlighting important advancements across Fintepla[®]▼(fenfluramine) oral solution and broader epilepsies portfolio

27 Jul 2023

UCB now at the inflection point – ready to start a new phase of growth

18 Jul 2023

UCB Announces EU Regulatory Filing for Bimekizumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

30 Jun 2023

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio at 9th Congress of the European Academy of Neurology (EAN) Meeting

27 Jun 2023

UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

26 Jun 2023

UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab

Press releases

Press releases

Search Press releases

UCB presents new data at 35th International Epilepsy Congress (IEC) highlighting important advancements across Fintepla[®]▼(fenfluramine) oral solution and broader epilepsies portfolio

UCB now at the inflection point – ready to start a new phase of growth

UCB Announces EU Regulatory Filing for Bimekizumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio at 9th Congress of the European Academy of Neurology (EAN) Meeting

UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Global data show real-world effectiveness of romosozumab for patients at high fracture risk

BIMZELX[®] (bimekizumab-bkzx) five-year data at AAD 2025 showed sustained skin clearance and long...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB presents new data at 35th International Epilepsy Congress (IEC) highlighting important advancements across Fintepla[®]▼(fenfluramine) oral solution and broader epilepsies portfolio

UCB now at the inflection point – ready to start a new phase of growth

UCB Announces EU Regulatory Filing for Bimekizumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio at 9th Congress of the European Academy of Neurology (EAN) Meeting

UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab

Choose a Country